This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;285:1148-1149.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2001;50:41-51

In 1988, the World Health Assembly resolved to eradicate poliomyelitis globally by 2000.¹ Substantial progress has been achieved toward this goal,^2-3 and with the circulation of wild poliovirus eliminated in most of the world, attention has focused on examining the potential for vaccine-derived poliovirus to circulate where wild poliovirus has disappeared. During 1999, sequences of historic poliovirus isolates were examined. This report summaries the results of that study, which indicate that oral poliovirus vaccine (OPV)-derived poliovirus type 2 circulated in Egypt during the 1980s and early 1990s and caused widespread infection and paralytic disease. The findings underscore the need for countries using OPV to target communities with low vaccine coverage for intense vaccination activities to prevent circulation of both wild and vaccine-derived polioviruses.

During 1988-1993, 32 polio cases associated with vaccine-derived poliovirus type 2 were found in eight of 27 governorates in Egypt. Although initial antigenic characterization of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Sabin 3-Derived Poliovirus Recombinant Contained a Sequence Homologous with Indigenous Human Enterovirus Species C in the Viral Polymerase Coding Region
Arita et al.
J. Virol. 2005;79:12650-12657.
ABSTRACT | FULL TEXT  

Ensuring Preparedness for Potential Poliomyelitis Outbreaks: Recommendations for the US Poliovirus Vaccine Stockpile From the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP)
NVAC-ACIP Joint Working Group and Centers for Dise
Arch Pediatr Adolesc Med 2004;158:1106-1112.
ABSTRACT | FULL TEXT  

Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains
Martin et al.
J. Gen. Virol. 2003;84:1781-1788.
ABSTRACT | FULL TEXT  

Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1
Blomqvist et al.
J. Gen. Virol. 2003;84:573-580.
ABSTRACT | FULL TEXT  

Isolation of an Intertypic Poliovirus Capsid Recombinant from a Child with Vaccine-Associated Paralytic Poliomyelitis
Martin et al.
J. Virol. 2002;76:10921-10928.
ABSTRACT | FULL TEXT  

Characterization of CHAT and Cox Type 1 Live-Attenuated Poliovirus Vaccine Strains
Martin and Minor
J. Virol. 2002;76:5339-5349.
ABSTRACT | FULL TEXT